Author: Healio ophthalmology

Anti-VEGF therapy effective in choroidal neovascularization with choroidal osteoma

PHILADELPHIA — Choroidal neovascularization and retinal exudation in patients with choroidal osteoma can be regulated with anti-VEGF therapy, according to a study presented here.Not only is anti-VEGF therapy efficacious in these patients, but it also helps preserve visual acuity, which is the ultimate goal in a benign tumor, M. Ali Khan, MD, said at the Wills Eye Institute Annual Conference.

Interferon gaining in treatment of ocular surface squamous neoplasia

PHILADELPHIA — Topical interferon is a viable alternative treatment for ocular surface squamous neoplasia, a speaker said here.”[A study] speculated that the future of therapy might be to focus on vaccines, antibiotics, antivirals and immune modulators,” Carol L. Shields, MD, said at the Wills Eye Institute Annual Conference. “Well, you know what? That future is now. We’re using less and less chemotherapy, radiotherapy and surgical excision for ocular surface squamous neoplasia, and we’re using the top four agents, interferon being the most commonly used. It is slow, it is effective, and the toxicity is minimal. Topical interferon is our topical drug of choice.”

Portable ETDRS chart offers advantages over standard chart

PHILADELPHIA — A pocket-sized ETDRS chart has the advantage of the high reproducibility of the standard ETDRS chart without the bulkiness, a speaker said here.While the Snellen chart is the most widely used eye chart, limitations apply, such as limited reproducibility, fluctuating background illumination, different number of letters on each line, and letters with different levels of difficulty to read.

Spectral domain OCT may detect macular thinning in primary open-angle glaucoma

PHILADELPHIA — Spectral domain optical coherence tomography successfully measured macular thickness in patients with open-angle glaucoma and unilateral visual field loss, a speaker said here.”Unilateral glaucoma and spectral domain OCT remains a promising model system for further longitudinal studies and may be able to define macular changes in the first affected eye,” Camilla S. Zangalli, MD, said at the Wills Eye Institute Annual Conference.

BLOG: FDA shares 5-year blueprint for designing more structured risk-benefit analysis

On March 8, the FDA published in the Federal Register a notice of the availability of its draft five-year plan describing the Agency’s approach to developing and implementing a structured framework for benefit-risk assessment.Publication of this plan fulfills one of FDA’s obligations under the Food and Drug Administration Safety and Innovation Act (FDASIA). The plan sets out FDA’s initial benefit-risk framework, which incorporates key decision factors of Analysis of Condition, Current Treatment Options, Benefit, Risk and Risk Management.

Treat and extend regimen for CRVO shows modest success

PHILADELPHIA — A treat-and-extend regimen of anti-VEGF therapy for macular edema from central retinal vein occlusion offered advantages but was less successful than a similar protocol for age-related macular degeneration, according to a study presented here.Advantages of a treat-and-extend regimen for CRVO included fewer office visits and injections, a lower risk of side effects and lower cost, Christopher J. Brady, MD, said at the Wills Eye Institute Annual Conference.

Glaucoma surgery improves quality of life but does not reduce rate of blindness

PHILADELPHIA — Despite steady improvements in recent decades, glaucoma surgery has a minimal impact on blindness from glaucoma in the United States, a guest speaker said here.“We really haven’t changed anything in 30 years, I’m sorry to say,” Peter A. Netland, MD, PhD, said during the Arthur J. Bedell Lecture at the Wills Eye Institute Annual Conference. “Glaucoma surgery really has a minimal impact on blindness due to glaucoma. Even if we had the perfect surgery, if it was 100% effective, zero complications, zero difficulty and 100% convenient … we’d still have similar rates of glaucoma and rates of blindness due to glaucoma today if we looked at our population in the United States.”

BLOG: It’s a great time to be a presbyope

Just a few years ago, I used to regularly make fun of my more senior friends and colleagues when they donned their reading glasses to see fine print. Now, at age 46, presbyopia doesn’t seem so funny anymore. Thankfully, a number of great technologies promise hope for us oldies. Personally, I love offering patients both the multifocal and accommodating IOLs that are approved but am very excited about newer, better IOL technologies. That is, if the FDA will ever approve them.More exciting still are the burgeoning technologies for the younger, emmetropic presbyope. Three corneal inlays are nearing approval in the U.S., and each offers promising results so far. The exciting thing about these inlays is they improve near vision in one eye while degrading distance vision much less than traditional monovision.

Seven new loci linked to AMD

Researchers have identified seven new loci linked to age-related macular degeneration, offering potential new avenues for biologic, therapeutic and genetic studies of the condition, according to a letter published by the AMD Gene Consortium.The researc…

ACA could increase demand for primary care, exceed supply by 10%

The Affordable Care Act’s expansion of insurance coverage could increase demand for primary care, thus exceeding services by 10%, according to data published in Health Affairs. Researchers who conducted the study have called for future policy research to meet the demand.“That increase, in turn, will boost demand for primary care services, potentially straining the primary care workforce and even limiting access to health care for both the newly and the currently insured,” the researchers wrote.

Genetic test for Avellino corneal dystrophy launched

The Avellino-Gene Detection System has been launched in the U.S. to help patients and physicians make a more informed decision before going forward with vision correction surgery, including LASIK, LASEK and PRK, according to a news release from Avellino Lab USA.The test can determine whether patients carry the Avellino corneal dystrophy gene mutation that puts them at higher risk for the disease, which causes corneal opacity and potential blindness, the release said. Laser surgery can exacerbate the problem, according to the company’s website.

BLOG: President’s sequestration order cuts Medicare payments to physicians and hospitals by 2%

President Obama signed the long-awaited sequestration order on March 1, officially cutting more than $85 billion from the federal budget for 2013. Coverage of these cuts, in both the popular media and trade press, has focused on the impact on programs for some of the country’s most vulnerable citizens. Perhaps most notably for older patients and those who care for them, however, roughly 12% of the total budget cuts (approximately $11 billion) will come from reductions to the Medicare budget.

Surgeon explains reimbursement changes amid new billing environment

SAN FRANCISCO — Surgeons face a mixed bag of reimbursement increases and decreases, based on revised guidelines and valuation changes, a surgeon said here.“I think [there’s] probably a lot of good news for those using the femtosecond [laser] with premium IOLs. There’s bad news for cataract, but some good news with respect to the reimbursement for [microincision glaucoma surgery],” David F. Chang, MD, said at the American Glaucoma Society annual meeting.